Daniel R. Chevallard has bought stock on 4 days since Jul 2017
CFO at LENZ Therapeutics, Inc., and 2 other companies
SEC CIK 0001706176 · Filings on SEC.gov ↗
Daniel R. Chevallard's record
3 months after each buy, from the first price a copier could get.
3 buys since 2017 with 3 months of prices.
Companies
Every filing
5 filings since Jul 2017, newest first
About Daniel R. Chevallard
Dan Chevallard (full name: Daniel R. Chevallard) is the Chief Financial Officer of Lenz Therapeutics, Inc. (LENZ), a biotechnology company, a position he has held since March 2024.( A seasoned finance executive with extensive experience in the biotechnology, pharmaceutical, and diagnostic industries, Chevallard previously served as Chief Operating Officer and Chief Financial Officer at Viracta Therapeutics, Inc., and as Chief Financial Officer at Regulus Therapeutics.( His career also includes significant roles at Prometheus Laboratories managing corporate accounting, financial reporting, and large R&D budgets, as well as five years in public accounting at Ernst & Young focusing on IPOs and Sarbanes-Oxley compliance.(
Chevallard holds a Bachelor of Arts in Accounting (or Bachelor of Accountancy) from the University of San Diego and is a Certified Public Accountant (inactive) in California.( As CFO of LENZ, he recently purchased 20 shares of company stock on November 7, 2025, for approximately $454, increasing his holdings to 3,208 shares.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.